ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Ethics Advisory Board to Consider Compensation Issue

September 7, 1979

The March, Sept. 26: Events Planned In D.C., Around The U.S.

September 4, 1998

Protection Commission Asks Hew To Adopt Entire Report As Policy for Human Subject Research

April 27, 1979

NCAB Approves, NCI Accepts Powers’ Version Of Board’s Organ Systems Recommendations

May 27, 1983

Phase III Ramucirumab Trial Fails Primary Endpoint of PFS

October 25, 2013

Race For The Cure Grants For National Capital Area.

June 29, 2001